Endometriosis Trial, Recruiting (NCT06773065)

Endometriosis Trial, Recruiting NCT06773065 Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna Condition: Endometriosis

Printed from Voxsanity (voxsanity.com.au) — NCT06773065 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Endometriosis

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Women who have been diagnosed with endometriosis through a physical exam, ultrasound, or surgery
Women between 18 and 50 years old
Women who are starting or are already taking hormone therapy for their condition
Women attending either a first appointment or a follow-up appointment at the clinic
Women who are willing to sign a consent form agreeing to take part in the study

Who may not be able to join:

Women who have gone through menopause, either naturally or as a result of medical treatment
Women who have never been sexually active (confirm with trial site)
Women who have not been taking their hormone therapy as prescribed, or who have stopped taking it on their own
Women who have a history of any type of cancer
Women who have a history of conditions that affect the brain or nervous system, such as brain or spinal cord injury, neurological diseases, nerve damage, or multiple sclerosis

⚠️ Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 23 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Diego Raimondo, MD, IRCCS Azienda Ospedaliero-Universitaria di Bologna

Phone: +393290636618

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06773065

Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna

Phase: Not Applicable

Status: Recruiting

Condition: Endometriosis

Trial contact: +393290636618

More information: https://clinicaltrials.gov/study/NCT06773065

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

Women who have been diagnosed with endometriosis through a physical exam, ultrasound, or surgery
Women between 18 and 50 years old
Women who are starting or are already taking hormone therapy for their condition
Women attending either a first appointment or a follow-up appointment at the clinic
Women who are willing to sign a consent form agreeing to take part in the study

Who may not be able to join:

Women who have gone through menopause, either naturally or as a result of medical treatment
Women who have never been sexually active (confirm with trial site)
Women who have not been taking their hormone therapy as prescribed, or who have stopped taking it on their own
Women who have a history of any type of cancer
Women who have a history of conditions that affect the brain or nervous system, such as brain or spinal cord injury, neurological diseases, nerve damage, or multiple sclerosis

⚠️ Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 23 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Registry

ClinicalTrials.gov

Start date

14 January 2022

Est. completion

31 January 2025

Where this trial is recruiting

🇮🇹 Italy

Primary endpoints

Prevalence of central sensitisation syndrome (CSS)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov